Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Update

Tempest Therapeutics, Inc. (NASDAQ:TPST) was the target of a significant decrease in short interest during the month of June. As of June 15th, there was short interest totaling 205,707 shares, a decrease of 39.7% from the May 31st total of 341,334 shares. Currently, 2.2% of the shares of the stock are sold short. Based on an average trading volume of 100,848 shares, the days-to-cover ratio is currently 2.0 days.

Tempest Therapeutics Stock Up 1.4%

Shares of NASDAQ TPST traded up $0.01 during midday trading on Wednesday, reaching $1.12. The company had a trading volume of 15,209 shares, compared to its average volume of 168,859. The stock has a market cap of $17.98 million, a PE ratio of -0.19 and a beta of -1.85. Tempest Therapeutics has a one year low of $1.02 and a one year high of $12.23. The firm’s fifty day moving average price is $1.58 and its 200-day moving average price is $2.13.

Tempest Therapeutics (NASDAQ:TPST) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($2.25). As a group, equities research analysts expect that Tempest Therapeutics will post -1.34 EPS for the current year.

Institutional Investors Weigh In On Tempest Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Tempest Therapeutics by 20.8% during the third quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock valued at $1,671,000 after acquiring an additional 27,952 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Tempest Therapeutics during the fourth quarter worth about $33,000. Finally, Sabby Management LLC bought a new stake in shares of Tempest Therapeutics in the fourth quarter worth about $513,000. 22.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on TPST. Wall Street Zen downgraded Tempest Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Zacks Research lowered Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Tempest Therapeutics has an average rating of “Reduce”.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.